Qingdao Huasaiberman Medical Cell Biology

Huasaiberman is a clinical-stage biotechnology company based in Qingdao, China, specializing in the development of next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for solid tumors. The company leverages its proprietary cell expansion and modification platforms to enhance the potency and persistence of T cells within the immunosuppressive tumor microenvironment. Its lead programs focus on treating refractory solid malignancies, including lung and gynecological cancers, where traditional therapies have limited efficacy. Huasaiberman aims to industrialize TIL therapy by optimizing manufacturing processes to reduce costs and turnaround times for patients.